UNSPSC 51370000: Controlled substance analgesics

This classification denotes agents that induce narcosis, originally, or agents that caused somnolence or induced sleep, but today, any derivative, natural or synthetic, of opium or morphine or any substance that has their effects. Controlled substances are potent inducers of analgesia.

UNSPSC 51370000 Controlled substance analgesics, a Family code, encompasses the procurement of pharmaceutical products including naloxone, opioid-antagonist medications, and related drug-management systems that state and local governments acquire for community health, emergency response, and substance-abuse mitigation programs. Recent solicitations show state and local buyers acquiring naloxone in bulk quantities (measured in thousands of units annually), safe drug deactivation systems, and generic pharmaceuticals through multi-jurisdictional cooperative purchasing agreements. The issuing bodies include county health departments, state health and human services commissions, and multi-state cooperative purchasing alliances that aggregate demand across member jurisdictions. Procurement typically follows fixed-price or volume-based models with quarterly or periodic delivery schedules, and vendors must comply with cGMP certification, Drug Supply Chain Security Act requirements, E-Verify verification, and federal compliance standards when federal funding (such as FEMA) is involved.

Recent activity spans Florida, Texas, and Minnesota. Seminole County, Florida issued IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with a July 26, 2023 response deadline and a two-year initial contract term with one-year renewal option. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026, to gather market intelligence on direct-to-manufacturer prescription fulfillment capabilities for a Therapeutic Pharmacy Initiative, signaling intent to establish future formal solicitations outside traditional pharmacy benefit manager and wholesaler channels. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issued RFP S1070000015802 on January 20, 2026, for generic multi-source pharmaceuticals and OTC products with a March 26, 2026 response deadline, requiring manufacturers to supply products through three authorized wholesalers (AmerisourceBergen Drug Corporation/Cencora, Cardinal Health, and Morris & Dickson) with contracts effective July 1, 2026, and pricing weighted 75 percent on competitiveness with administrative fees of 3 percent and performance penalties of $200 to $1,500 per violation.